491833-29-5 | Eliglustat

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$60.00	$42.00
5mg	98%	in stock	$75.00	$52.00
25mg	98%	in stock	$125.00	$87.00
50mg	98%	in stock	$160.00	$112.00
250mg	98%	in stock	$536.00	$375.00

Description

• Catalog Number: AG20964
• Chemical Name: Eliglustat
• CAS Number: 491833-29-5
• Molecular Formula: C23H36N2O4
• Molecular Weight: 404.5429
• MDL Number: MFCD19443735
• SMILES: CCCCCCCC(=O)N[C@@H]([C@@H](c1ccc2c(c1)OCCO2)O)CN1CCCC1

Computed Properties

• Complexity: 484
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 2
• Heavy Atom Count: 29
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 11
• XLogP3: 3.7

Literature

• Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment.

  Blood cells, molecules & diseases 20141201

• Eliglustat: first global approval.

  Drugs 20141001

• Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain.

  Journal of lipid research 20120201

• Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.

  Journal of medicinal chemistry 20110224

• Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study.

  Blood 20101118

• Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases.

  Current opinion in investigational drugs (London, England : 2000) 20101001

• A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1.

  Blood 20100812

• Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy.

  Journal of inherited metabolic disease 20100601

• Increased hepatic insulin action in diet-induced obese mice following inhibition of glucosylceramide synthase.

  PloS one 20100101

• Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.

  PloS one 20100101

• A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease.

  Molecular genetics and metabolism 20070701